Skip to main content
Otto Metzger, MD, Oncology, Boston, MA

OttoMetzgerMD

Oncology Boston, MA

Breast Cancer

Dana Farber Cancer Institute Harvard Medical School Executive Officer The Alliance for Clinical Trials in Oncology Foundation

Dr. Metzger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Metzger's full profile

Already have an account?

  • Office

    450 Brookline Ave
    Boston, MA 02215
    Phone+1 617-632-3800

Education & Training

  • Universite Libre de Bruxeles
    Universite Libre de BruxelesPhD, Breast Cancer, 2009 - 2013
  • Federal University of Minas Gerais
    Federal University of Minas GeraisClass of 2003

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2013 - 2025

Awards, Honors, & Recognition

  • Clinical Scholar Award San Antonio Breast Cancer Symposium, 2010

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first line trastuzu...  
    Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU, Clin Breast Cancer, 8/1/2013
  • The magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: Results from the HERA trial  
    Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R..., J Clin Oncol, 6/1/2013
  • Analysis of Regional Timelines to Set up a Global Phase III Clinical Trial in Breast Cancer: The ALTTO Experience  
    Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu ..., Oncologist, 1/1/2013
  • Join now to see all

Lectures

  • HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Surgery May Be Unnecessary for Common Precancerous Breast Condition
    Surgery May Be Unnecessary for Common Precancerous Breast ConditionDecember 14th, 2024
  • Phase III PATINA Study Shows Hope for HR+, HER2+ Cancer
    Phase III PATINA Study Shows Hope for HR+, HER2+ CancerDecember 13th, 2024
  • CDK 4/6 Inhibitor Boosts HR+, HER2+ Breast Cancer Care
    CDK 4/6 Inhibitor Boosts HR+, HER2+ Breast Cancer CareDecember 12th, 2024
  • Join now to see all

Professional Memberships

Other Languages

  • Portuguese, French